Get it on Google Play

FDA clears Prime Medicine's IND for AATD gene editing therapy

September 24, 2026 4:01 PM EDT Send to a Friend
Prime Medicine, Inc. (Nasdaq: PRME) announced that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login